Landanger Camus benefits from AMP acquisition
This article was originally published in Clinica
Executive Summary
Revenues at French orthopaedic implant manufacturer Landanger Camus increased to Fr 441 million ($88 million) in fiscal 1995, up 7.3% compared with last year. The company says without the acquisition of ankle prosthesis producer AMP earlier this year (see Clinica No 652, p 1), turnover would have risen only 3.8%. Foreign sales accounted for around 27% of sales for the year.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.